Our core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform blood test.with advanced machine learning to diagnose disease from a simple
ClarityDX Prostate, our lead product currently in clinical trials, is designed to be a highly accurate test to predict clinically significant prostate cancer.This technology is positioned to emerge as the leading diagnostic tool, bringing clarity to healthcare decisions for prostate cancer.
Please note: this product is in development and so currently has not received regulatory approval or clearance in any markets.
Nanostics is a Canadian company with offices in Edmonton, Alberta.The company is privately held by the founders and a small group of investors.
Please contact us about opportunities to invest in Nanostics.